Patents by Inventor Francesca Magnani
Francesca Magnani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052017Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: April 21, 2023Publication date: February 15, 2024Applicant: HEPTARES THERAPEUTICS LIMITEDInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20230287348Abstract: The invention provides a method for the improved generation of genetically modified cells in vitro, in order to obtain a population of effector cells with immunotherapeutic activity and methods of using such cells in protocols for adoptive cell therapy. The invention further provides non-viral genetically modified cells, cell populations and cell cultures and the use thereof in the treatment or prevention of diseases and disorders.Type: ApplicationFiled: December 29, 2022Publication date: September 14, 2023Inventors: Andrea BIONDI, Ettore BIAGI, Chiara Francesca MAGNANI, Sarah TETTAMANTI
-
Patent number: 11673938Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: GrantFiled: May 11, 2020Date of Patent: June 13, 2023Assignee: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Patent number: 11572542Abstract: The invention provides a method for the improved generation of genetically modified cells in vitro, in order to obtain a population of effector cells with immunotherapeutic activity and methods of using such cells in protocols for adoptive cell therapy. The invention further provides non-viral genetically modified cells, cell populations and cell cultures and the use thereof in the treatment or prevention of diseases and disorders.Type: GrantFiled: November 6, 2015Date of Patent: February 7, 2023Assignee: FONDAZIONE MATILDE TETTAMANTI E MENOTTI DE MARCHI ONLUSInventors: Andrea Biondi, Ettore Biagi, Chiara Francesca Magnani, Sarah Tettamanti
-
Publication number: 20210148939Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.Type: ApplicationFiled: November 30, 2020Publication date: May 20, 2021Applicant: Heptares Therapeutics LimitedInventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
-
Publication number: 20210061882Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: May 11, 2020Publication date: March 4, 2021Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20190241644Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: December 10, 2018Publication date: August 8, 2019Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20190211307Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: ApplicationFiled: February 28, 2019Publication date: July 11, 2019Applicants: Yale University, Ospedale San Raffaele S.r.l, Fondazione TelethonInventors: Richard A. FLAVELL, Nicola GAGLIANI, Silvia GREGORI, Samuel HUBER, Chiara Francesca MAGNANI, Maria Grazia RONCAROLO
-
Patent number: 10260042Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: GrantFiled: September 21, 2017Date of Patent: April 16, 2019Assignees: Yale University, Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Richard A. Flavell, Nicola Gagliani, Silvia Gregori, Samuel Huber, Chiara Francesca Magnani, Maria Grazia Roncarolo
-
Publication number: 20190094247Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.Type: ApplicationFiled: October 4, 2018Publication date: March 28, 2019Applicant: Heptares Therapeutics LimitedInventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
-
Patent number: 10126313Abstract: A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular formation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.Type: GrantFiled: January 6, 2016Date of Patent: November 13, 2018Assignee: Heptares Therapeutics LimitedInventors: Malcolm Peter Weir, Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne
-
Publication number: 20180119099Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: ApplicationFiled: September 21, 2017Publication date: May 3, 2018Inventors: Richard A. FLAVELL, Nicola GAGLIANI, Silvia GREGORI, Samuel HUBER, Chiara Francesca MAGNANI, Maria Grazia RONCAROLO
-
Publication number: 20180086814Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: September 26, 2017Publication date: March 29, 2018Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20170355957Abstract: The invention provides a method for the improved generation of genetically modified cells in vitro, in order to obtain a population of effector cells with immunotherapeutic activity and methods of using such cells in protocols for adoptive cell therapy. The invention further provides non-viral genetically modified cells, cell populations and cell cultures and the use thereof in the treatment or prevention of diseases and disorders.Type: ApplicationFiled: November 6, 2015Publication date: December 14, 2017Inventors: Andrea BIONDI, Ettore BIAGI, Chiara Francesca MAGNANI, Sarah TETTAMANTI
-
Publication number: 20160052991Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: August 26, 2015Publication date: February 25, 2016Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20150132272Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: ApplicationFiled: June 18, 2013Publication date: May 14, 2015Inventors: Richard A. Flavell, Nicola Gagliani, Silvia Gregori, Samuel Huber, Chiara Francesca Magnani, Maria Grazia Roncarolo
-
Patent number: 8785135Abstract: The present invention relates in some aspects to mutant G protein coupled receptors (GPCRs) and methods for selecting those with increased stability. In certain aspects, the invention relates to the selection and preparation of mutant GPCRs which have increased stability under a particular condition compared to their respective parent proteins.Type: GrantFiled: March 20, 2008Date of Patent: July 22, 2014Assignee: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
-
Publication number: 20120270230Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.Type: ApplicationFiled: June 11, 2012Publication date: October 25, 2012Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Wame, Malcolm Peter Weir
-
Publication number: 20100190188Abstract: A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising (a) providing one or more mutants of a parent GPCR, (b) selecting a ligand, the ligand being one which hinds to the parent GPCR when the GPCR is residing in a particular conformation, (c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and (d) selecting those mutants that have an increased stability compared to the parent GPCR with respect to binding the selected ligand. Mutants of ?-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed.Type: ApplicationFiled: March 20, 2008Publication date: July 29, 2010Applicant: Heptares Therapeutics LimitedInventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir